Navigation Links
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Date:6/17/2008

ocument.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >CTIC; MTA) management team will host a conference call to discuss the company's recent agreement to access the Zevalin(R) FIT trial data from Bayer Schering Pharma.

Conference Call Numbers

Wednesday, June 18

8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time

1-800-240-7305 (US Participants)

1-303-262-2140 (International)

Call-back numbers for post-listening available at 11:30 a.m. Eastern:

1-800-405-2236 (US Participants)

1-303-590-3000 (International)

Passcode: 11116122#

Live audio webcast at http://www.celltherapeutics.com will be archived for post listening approximately two hours after call ends.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of Zevalin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Zevalin in particular including, without limitation, the potential failure of the Zevalin FIT data to be suitable for submission or acceptable to the FDA for this expanded indication, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin. There is also a risk that even if label expansion of Zevalin is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. In addition, there is a risk that we may not be able to recognize the full expected value of Zevalin in future years. You should also revie
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
2. Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center
3. CyberKnife Radiosurgery Used to Treat Lung Tumors at 90 Percent of Centers Worldwide
4. Chromos enters into loan and lending arrangements
5. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
6. CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order
7. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
8. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
9. Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
10. Finesse Solutions Expands by Opening Sales and Service Centers
11. Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... primary commercial focus on China , ... C meeting with the U.S. Food and Drug Administration ... February 2015.  During this meeting the Company will seek ...
(Date:12/17/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... for rare disorders, announced today its presentation at the ... San Francisco, CA. ... will present on Monday, January 12, 2015, at 9:00 ... webcast live and may be accessed from the "Webcasts ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... Total Site Solutions,(TSS), a Fortress International Group Company ... the planning, design and development of,mission-critical facilities today ... industry has awarded them the construction,management phase of ... performed technology consulting services to analyze,short term and ...
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... leader in,the rapidly evolving field of cancer molecular diagnostics, ... Lindenbergh as Chairman of its,Supervisory Board. Hessel Lindenbergh ... ING,Group N.V.. Currently, Mr. Lindenbergh is chairman of the ... the Royal Numico, Petroplus,International and Gamma Holding. Mr. Lindenbergh ...
Cached Biology Technology:Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 2Total Site Solutions Selected to Provide Construction Management Services for Existing Pharmaceutical and Biotech Customer for Data Center Expansion Project 3Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board 2
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
(Date:11/18/2014)... , Nov. 17, 2014 The Parenteral Drug ... U.S. regulatory agencies will speak and at least seven more ... Conference at the Omni Shoreham Hotel in Washington ... once again to have significant support from the regulatory agencies ... Europe in our effort to help advance ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... a study has compared water quality trends in forested streams ... or land cover changes. The study, which draws on ... states and Puerto Rico, underscores the value of long-term data ... in streams and rivers. It is published in the current ...
... sick with colon cancer, received a blood transfusion. Then, unexpectedly, ... on her case, the French medical journal Revue D,Hmatologie identified ... it turns out, Mrs. Vel had developed a potent antibody ... of most people in the worldbut not found on her ...
... Philanthropist, businessman and community leader John Moores has given ... fund the development of a new field test for ... tens of millions of people in Africa, Latin America ... John,s generosity and foresight," said Michael A. Marletta, president ...
Cached Biology News:Study explores long-term water quality trends in near-pristine streams 2Baffling blood problem explained 2Baffling blood problem explained 3John Moores gives $2 million to Scripps Research to develop river blindness field test 2
... Freedom EVO series offers versatile liquid handling ... automate a wide variety of life science ... different base sizes (75, 100, 150 and ... to a platform that will advance with ...
... accurately and conveniently controls the temperature at your ... temperature levels up to 99 C*, with the ... low as 5 C. The thermoblocks for 0.2 ... and microplates enable a high degree of flexibility ...
384 Well PCR Plate Carrier for Thermo-Sealer...
... Cultures (ECACC) has been offering training courses ... institutes for over seven years. We offer ... candidates to cell culture and a Level ... areas such as planning and management of ...
Biology Products: